While Vor Biopharma Inc has underperformed by -3.08%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VOR fell by -56.08%, with highs and lows ranging from $65.80 to $2.62, whereas the simple moving average fell by -60.19% in the last 200 days.
On October 15, 2025, Robert W. Baird Upgraded Vor Biopharma Inc (NASDAQ: VOR) to Outperform. A report published by Stifel on September 24, 2025, Upgraded its rating to ‘Buy’ for VOR. H.C. Wainwright also Upgraded VOR shares as ‘Buy’, setting a target price of $3 on the company’s shares in a report dated June 30, 2025. Wedbush Initiated an Outperform rating on July 26, 2022, and assigned a price target of $18. Goldman initiated its ‘Neutral’ rating for VOR, as published in its report on April 27, 2022. H.C. Wainwright’s report from December 17, 2021 suggests a price prediction of $26 for VOR shares, giving the stock a ‘Buy’ rating. Robert W. Baird also rated the stock as ‘Outperform’.
Analysis of Vor Biopharma Inc (VOR)
To gain a thorough understanding of Vor Biopharma Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -125.43% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.49, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and VOR is recording an average volume of 526.47K. On a monthly basis, the volatility of the stock is set at 9.03%, whereas on a weekly basis, it is put at 9.40%, with a loss of -48.60% over the past seven days. Furthermore, long-term investors anticipate a median target price of $45.50, showing growth from the present price of $9.75, which can serve as yet another indication of whether VOR is worth investing in or should be passed over.
How Do You Analyze Vor Biopharma Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 17.06%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 20.65% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
